FREQUENCY THERAP(FREQ) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs CAMBRIDGE, Mass., November 12, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today provided a program update for its Phase 1/2a REWRITE clinical trial of KRRO-110 in AATD, r ...